Triomics Secures $22M Funding to Revolutionize Oncology Data Management

Triomics, an emerging tech company specializing in artificial intelligence (AI) solutions for the healthcare industry, has secured a significant $22 million investment in its Series B round. The financing was led by Battery Ventures with additional support from existing investors Nexus Venture Partners, Lightspeed, and Y Combinator.

The rise of advanced AI technologies is paving the way for more efficient and effective patient care. However, this progress comes at a cost: healthcare providers are now grappling with increasingly complex and extensive medical records that can span thousands of pages. These records include detailed physician notes, imaging reports, pathology data, and even faxes—tasks that are both time-consuming and challenging to navigate.

From Clinical Trials to Patient Summaries

Founded in 2021, Triomics began by helping oncologists identify the most appropriate clinical trials for their patients. Over the past few years, the company has expanded its offerings significantly. Thanks to advancements in large language models (LLMs), Triomics now provides verifiable patient summaries directly within the tools clinicians use daily. This integration streamlines processes and reduces appointment prep time, allowing oncologists more face-to-face time with their patients.

Automating Tumor Reporting

In addition to clinical trial matching, Triomics automates another critical administrative task: submitting tumor reports to government registries. These are legally mandated tasks that can be tedious and labor-intensive for healthcare staff. By leveraging AI, Triomics ensures these submissions are accurate and timely, further reducing the administrative burden on staff.

Competing in a Crowded Market

Despite facing competition from established players like Abridge and Microsoft’s Nuance, which use AI to summarize patient interactions, Triomics stands out due to its specialized training on oncology data. This tailored approach makes it particularly valuable for institutions such as Memorial Sloan Kettering (MSK) and Yale Cancer Center.

Fast Growth and Strong Demand

The startup's success is evident in its rapid expansion over the past year. According to Sarim Khan, co-founder and CEO of Triomics, the company’s enterprise customer base has grown fourfold, driving a 10-fold increase in annualized recurring revenue.